NEW YORK (GenomeWeb News) - Genizon BioSciences said today that it has closed a Series E financing round worth CAD$31 million (US$30.8 million) that it will use to support genome-wide association studies for metabolic syndrome.
BTF, a venture capital fund based in the Netherlands, was the lead investor for the round.
Genizon said the new financing brings its total funding since it was founded in 1999 to more than $130 million.
The company said it will use the new funding to support genome-wide association studies in obesity, type 2 diabetes, dyslipidemia, and hypertension. The company said it will also evaluate links between metabolic syndrome, coronary heart disease, and Alzheimer's disease, and will study genes it has discovered in longevity “that appear to protect against these diseases.”